^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    M701

    i
    Other names: M701
    Associations

    News

    Trials
    Company:
    YZY Biopharma
    Drug class:
    CD3 agonist, EPCAM inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody (clinicaltrials.gov)
    P3, N=270, Recruiting, Wuhan YZY Biopharma Co., Ltd.
    New P3 trial • Metastases
    |
    EPCAM (Epithelial cell adhesion molecule)
    |
    M701
    9ms
    Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody (clinicaltrials.gov)
    P2, N=80, Active, not recruiting, Wuhan YZY Biopharma Co., Ltd.
    New P2 trial
    |
    M701
    2years
    A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC (clinicaltrials.gov)
    P1/2, N=96, Not yet recruiting, Wuhan YZY Biopharma Co., Ltd.
    New P1/2 trial
    |
    EPCAM (Epithelial cell adhesion molecule)
    |
    EPCAM expression
    |
    cisplatin • M701